Canaccord lowered the firm’s price target on Doximity (DOCS) to $30 from $34 and keeps a Buy rating on the shares. The firm said their buy thesis remains intact as they believe the company will still be a likely AI winner. Canaccord believes the weakness was attributed to an AI competitor’s guide down by pharma marketing peer OptimizeRx conveying continued pharma budget strains.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity price target lowered to $35 from $49 at Morgan Stanley
- Doximity price target lowered to $24 from $28 at Goldman Sachs
- Doximity price target lowered to $25 from $31 at Leerink
- Doximity downgraded to Neutral from Buy at BTIG
- Doximity Maintained at Buy as Analyst Sees Temporary Profit Trough and Long-Term Upside with Unchanged $47 Price Target